Abrdn Life Sciences Investors (NYSE:HQL) Sees Large Drop in Short Interest

Abrdn Life Sciences Investors (NYSE:HQL) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 33,800 shares, a drop of 54.4% from the November 15th total of 74,100 shares. Based on an average trading volume of 75,400 shares, the short-interest ratio is presently 0.4 days.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

Several hedge funds have recently bought and sold shares of HQL. Commonwealth Equity Services LLC grew its position in shares of Abrdn Life Sciences Investors by 2.6% in the second quarter. Commonwealth Equity Services LLC now owns 33,788 shares of the company’s stock valued at $479,000 after purchasing an additional 868 shares during the last quarter. Stephens Inc. AR grew its position in shares of Abrdn Life Sciences Investors by 7.6% in the third quarter. Stephens Inc. AR now owns 12,707 shares of the company’s stock valued at $192,000 after purchasing an additional 896 shares during the last quarter. Wedbush Securities Inc. grew its position in shares of Abrdn Life Sciences Investors by 8.2% in the second quarter. Wedbush Securities Inc. now owns 16,673 shares of the company’s stock valued at $236,000 after purchasing an additional 1,261 shares during the last quarter. Sanctuary Advisors LLC grew its position in shares of Abrdn Life Sciences Investors by 11.4% in the third quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock valued at $183,000 after purchasing an additional 1,355 shares during the last quarter. Finally, Future Financial Wealth Managment LLC acquired a new stake in shares of Abrdn Life Sciences Investors in the third quarter valued at about $30,000. 32.21% of the stock is owned by institutional investors and hedge funds.

Abrdn Life Sciences Investors Trading Down 1.0 %

Abrdn Life Sciences Investors stock traded down $0.14 during mid-day trading on Friday, hitting $13.84. 73,123 shares of the company’s stock were exchanged, compared to its average volume of 92,054. Abrdn Life Sciences Investors has a 1-year low of $12.76 and a 1-year high of $15.90. The stock has a 50 day moving average of $14.58 and a two-hundred day moving average of $14.70.

Abrdn Life Sciences Investors Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 10th. Shareholders of record on Thursday, November 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 14.45%. This is an increase from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 21st.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.